Table 4. Real world data studies with more than 100 patients evaluating OS with immunotherapy in previously treated advanced NSCLC.
| Author | Sample size | Treatment | Median OS (months) | Median PFS (months) | Factors influencing OS | Toxicity profile |
|---|---|---|---|---|---|---|
| Garde-Noguera et al. [99] | 175 2L: 75≥3L: 100 | Nivolumab | 5.81 | 2.8 | -PS 2 - Time since previous treatment<6 months - Number metastatic locations |
Grade 3–4 AE=11.4% Most common AE: fatigue (10.6%), skin toxicity (9.7%) |
| Areses et al. [100] | 188 | Nivolumab | 12.85 | 4.83 | -CNS metastases - ECOG PS |
Treatment related AE=78% Grade 3–4 AE=4.8% |
| Mielgo-Rubio et al. [101] | 168 | Nivolumab 155 Pembrolizumab 13 | 11.4 | 5.6 | -LIPI index - Antibiotic use |
|
| Rodriguez-Abreu et al. [102] | 665 2L: 239 3L: 224≥4L: 202 | Nivolumab | 8.97 | 3.23 | All grade AE=44.5% Grade 3–4 AE=10.4% |
|
| Dixmier et al. [103] | 1837 | Nivolumab | 11.5 | Treatment related AE=31% Grade 3–4 AE=7% |
||
| Chouaid et al. [104] | 10452 | Nivolumab | Non-squamous 14.2 Squamous 10.5 |
|||
| Grossi et al. [105] | 1588 | Nivolumab | 11.3 | 3 | -ECOG PS - Liver metastasis |
All grade irAE=32% Grade 3–4 irAE=6% |
| Crinò et al. [106] | 371 | Nivolumab | 12.8 | 4.8 | -ECOG PS - Liver metastasis - Bone metastasis |
All grade irAE=29% Grade 3–4 irAE=6% |
| Juergens et al. [107] | 472 | Nivolumab | 12 | 3.5 | -ECOG PS - CNS metastasis - EGFR mutations |
|
| Morita et al. [108] | 901 | Nivolumab | 14.6 | 2.1 | -ECOG PS - Liver metastasis |
All grade irAE=45.8% Grade 3–4 irAE=14% |
| Khozin et al. [109] | 1344 | Nivolumab and pembrolizumab | 8 | -EGFR mutations - ALK translocation |
||
| Khozin et al. [110] | 5257 | Nivolumab, pembrolizumab and atezolizumab | 9.3 | 3.2 | -EGFR mutations - ALK translocation -Hepatic dysfunction |
|
| Figueiredo et al. [111] | 219 | Nivolumab | 13.2 | 4.9 | -ECOG PS | All grade irAE=76.4% Grade 3–4 irAE=18.2% |
| Karak et al. [112] | 110 | Nivolumab and pembrolizumab | 8.1 | 4 | All grade irAE=18% | |
| Ahn et al. [113] | 155 | Nivolumab and pembrolizumab | 10.2 | 3.1 | -ECOG PS - EGFR mutations - ALK rearrangement - Liver metastasis |
All grade irAE=61.9% Grade 3–4 irAE=5.3% |
| Nadler et al. [114] | 1020 2L: 718 3L: 302 |
Nivolumab and pembrolizumab | 2L: 9.7 3L: 11.3 |
|||
| Weis et al. [115] | 124 | Nivolumab and atezolizumab | Nivolumab: 8.4 Atezolizumab: 6.5 |
Nivolumab: 2.2 Atezolizumab: 2 |
-ECOG PS | All grade irAE=70.4/65.1% |